for the Period Ended 30 June 2024
Balance sheet | |
Additional notes | |
Community Interest Report |
As at
Notes | 2024 | 2023 | |
---|---|---|---|
|
£ |
£ |
|
Fixed assets | |||
Intangible assets: |
|
|
|
Tangible assets: |
|
|
|
Investments: |
|
|
|
Total fixed assets: |
|
|
|
Current assets | |||
Stocks: |
|
|
|
Debtors: |
|
|
|
Cash at bank and in hand: |
|
|
|
Investments: |
|
|
|
Total current assets: |
|
|
|
Prepayments and accrued income: |
|
|
|
Creditors: amounts falling due within one year: |
|
|
|
Net current assets (liabilities): |
|
|
|
Total assets less current liabilities: |
|
|
|
Creditors: amounts falling due after more than one year: |
|
|
|
Provision for liabilities: |
|
|
|
Accruals and deferred income: |
|
|
|
Total net assets (liabilities): |
|
|
|
Members' funds | |||
Profit and loss account: |
|
|
|
Total members' funds: |
|
|
The notes form part of these financial statements
The directors have chosen not to file a copy of the company's profit and loss account.
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 30 June 2024
Basis of measurement and preparation
for the Period Ended 30 June 2024
2024 | 2023 | |
---|---|---|
Average number of employees during the period |
|
|
The company plans to provide pharmaceuticals to the community at a not for profit cost.
No consultation with stakeholders
No remuneration was received
No transfer of assets other than for full consideration
This report was approved by the board of directors on
26 September 2024
And signed on behalf of the board by:
Name: Misha Engineer
Status: Director